Johnson & Johnson completes acquisition of Shockwave Medical, Inc. to expand its presence in cardiovascular intervention

Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire all outstanding shares of Shockwave Medical, Inc. (Nasdaq: SWAV) for $335.00 per share in cash, with a total enterprise value of approximately $13.1 billion. This acquisition will further extend Johnson & Johnson's position in the cardiovascular intervention market, providing an opportunity to accelerate their impact and drive greater value for patients, shareholders, and health systems. Shockwave's IVL technology for treating CAD and PAD, and its strong pipeline, are expected to enhance Johnson & Johnson's leadership position in medtech and expand into additional high-growth segments.